DeFloria Receives Investigational New Drug Application Clearance From FDA for Cannabinoid Drug to Treat Autism Spectrum Disorder
DeFloria plans to initiate a Phase 2 clinical trial by mid-year 2025.
DeFloria plans to initiate a Phase 2 clinical trial by mid-year 2025.